Cargando…
Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers
BACKGROUND: Rare disease patients and caregivers face uncommon, serious, debilitating conditions often characterised by poor prognosis and limited treatment options. This study aimed to explore what they consider of value when choosing between hypothetical therapeutic options and to quantify both th...
Autores principales: | Morel, T., Aymé, S., Cassiman, D., Simoens, S., Morgan, M., Vandebroek, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881055/ https://www.ncbi.nlm.nih.gov/pubmed/27225337 http://dx.doi.org/10.1186/s13023-016-0444-9 |
Ejemplares similares
-
Quantifying Benefit-Risk Preferences for Heart Failure Devices: A Stated-Preference Study
por: Reed, Shelby D., et al.
Publicado: (2021) -
Off-label use of orphan medicinal products: a Belgian qualitative study
por: Dooms, Marc, et al.
Publicado: (2016) -
Shining a light in the black box of orphan drug pricing
por: Picavet, Eline, et al.
Publicado: (2014) -
Development and validation of COMPASS: clinical evidence of orphan medicinal products – an assessment tool
por: Picavet, Eline, et al.
Publicado: (2013) -
What Does Society Value About Cancer Medicines? A Discrete Choice Experiment in the Belgian Population
por: Pauwels, Kim, et al.
Publicado: (2019)